# US 2021/0171928 A1 · Compositions and methods for treating celiac sprue disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171928 A1
- Document ID: US20210171928A1
- Status: Published application
- Kind: A1
- Application number: 17/019,497
- Filed: 2020-09-14
- Published: 2021-06-10
- Earliest claimed: 2015-06-08
- Assignees: University of Washington; The Regents of the University of California
- Applicants: University of Washington; The Regents of the University of California
- Inventors: Ingrid Swanson PULTZ; Clancey WOLF; Justin Bloomfield SIEGEL; Christine Elaine TINBERG; Lance STEWART; David BAKER
- Web page: https://patentgrep.com/patent/US20210171928A1

## CPC

- C12N 9/50: Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- C12N 9/52: derived from bacteria {or Archaea}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, are provided, wherein (a) the polypeptide degrades a PFQFQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.

## Claims

### Claim at position 1

1-41. (canceled)

### Claim 42

A method for treating celiac sprue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual with celiac sprue or NCGS a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 1, wherein (a) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (b) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 463A/L/M/Q/R/T/V, 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 320M, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, 105H, 171R/A/S, 172R/A/S, 173R/S, 174S, and 456V, in an amount effective to treat the celiac sprue or NCGS.

### Claim 43

(canceled)

### Claim 44 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 463A/L/M/Q/R/T/V, 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/TN, 319A, 320M, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, and 461R.

### Claim 45 (depends on 42)

The method of claim 42, comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1.

### Claim 46 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, and 463A/L/M/Q/R/T/V.

### Claim 47 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 1 at two or more residues selected from the group.

### Claim 48 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of:
(a) 399Q and 449E/N/Q;
(b) 399Q and 449Q;
(c) 358S and 463T;
(d) 262E, 269T, 354Q, 358S, 399Q, 449Q, and 463T;
(e) 319A, 368F, 399Q, 449Q, and I463T;
(f) 262E, 269T, 270V, 354Q, 358S, 399Q, and A449Q;
(g) 262E, 269T, 320M, 354Q, 358S, 399Q, 449Q, and 463T; and
(h) 319A, 320M, 368F, 399Q, 449Q, and 463T.

### Claim 49 (depends on 42)

The method of claim 42, comprising an amino acid change from SEQ ID NO: 1 at one or more amino acid positions selected from the group consisting of 105H, 171R/A/S, 172R/A/S, 173R/S, 174S, and 456V.

### Claim 50

A method for treating celiac sprue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual with celiac sprue or NCGS a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 71, wherein (a) residue 278 is Ser, residue 78 is Glu, and residue 82 is Asp; and (b) the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 274A/L/M/Q/R/T/V, 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81NTN, 130A, 131M 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 267V, and 272R, in an amount effective to treat the celiac sprue or NCGS.

### Claim 51 (depends on 50)

The method of claim 50, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 274A/L/M/Q/R/T/V, 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81NTN, 130A, 131M 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, and 272R.

### Claim 52 (depends on 50)

The method of claim 50, wherein the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 71.

### Claim 53 (depends on 50)

The method of claim 50, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81A/TN, 130A, 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 272R, and 274A/L/M/Q/R/T/V.

### Claim 54 (depends on 50)

The method of claim 50, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 71 at two or more residues selected from the group.

### Claim 55 (depends on 50)

The method of claim 50, wherein the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of:
(a) 210Q and 260E/N/Q.
(b) 210Q and 260Q;
(c) 169S and 274T;
(d) 73E, 80T, 165Q, 169S, 210Q, 260Q, and 274T
(e) 130A, 179F, 210Q, 260Q, and 274T;
(f) 73E, 80T, 81V, 165Q, 169S, 210Q, and 260Q;
(g) 73E, 80T, 320M, 165Q, 169S, 210Q, 260Q, and 274T; and
(h) 267V.

### Claim 56 (depends on 42)

The method of claim 42, wherein the polypeptide further comprises a histidine tag at the C-terminus of the polypeptide, including but not limited to the amino acid sequence GSTENL YFQSGALEHHHHHH (SEQ ID NO: 139).

### Claim 57 (depends on 42)

The method of claim 42, wherein the histidine tag comprises a cleavable histidine tag, including but not limited to a cleavable histidine tag comprising the amino acid sequence XNPQ(L/Q)PXNHHHHHH (SEQ ID NO: 131), wherein XN is an linker of between 1-25 amino acid residues.

### Claim 58 (depends on 57)

The method of claim 57, wherein the cleavable histidine tag comprises the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 132).

### Claim 59 (depends on 42)

The method of claim 42, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 129.

### Claim 60 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid sequence at least 99% identical to SEQ ID NO: 59.

### Claim 61 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid sequence at least 99% identical to SEQ ID NO: 59, wherein said amino acid sequence comprises the amino acid sequence set forth in SEQ ID NO: 129.

### Claim 62 (depends on 42)

The method of claim 42, wherein the polypeptide comprises an amino acid sequence at least 99% identical to SEQ ID NO: 59, which includes at least one amino acid deletion from SEQ ID NO: 59.

### Claim 63 (depends on 42)

The method of claim 42, wherein the polypeptide is administered orally.
